Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01414075 · ClinicalTrials.gov registry record · Phase 2
Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment
A Phase 2 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01414075 is a Phase 2 study that has completed, run by Kyntra Bio. The registered enrollment target is 60 participants.
The verdict
NCT01414075, a Phase 2 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.
Interventions
- DRUG Roxadustat
- DRUG Oral Iron
- DRUG IV Iron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-07-21 |
| Est. Completion | 2013-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01414075
The ClinicalTrials.gov registry entry for NCT01414075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Roxadustat is the first listed.
NCT01414075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01414075 about?
NCT01414075 is a clinical study titled "Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment". The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.
What is the current status of trial NCT01414075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2011-07-21. Estimated completion is 2013-01-10.
What interventions are being tested in trial NCT01414075?
The interventions under investigation include: Roxadustat (DRUG), Oral Iron (DRUG), IV Iron (DRUG).
Who is sponsoring clinical trial NCT01414075?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.